DALLAS, Oct. 16, 2006 (PRIMEZONE) -- John Pentony, Publisher of StockGuru.com, announced today that the web site has initiated Profile Coverage of GeneThera Inc. (OTCBB:GTHA). GeneThera is based on its Integrated Technology Platform (ITP) that combines a proprietary diagnostic solution called Gene Expression Assay (GEA(tm)) with PURIVAX(tm), its system for analyzing large-scale DNA sequencing. The first part of this platform is the ongoing development of molecular diagnostic assays solutions using Real Time Fluorogenic Polymerase Chain Reaction (F-PCR) technology to detect the presence of infectious disease from the blood of live animals. The second part of the ITP is the development of therapeutic vaccines using RNA interference technology. It also allows for the efficient, effective, and continuous testing, management and treatment of animal populations. These facts distinguish the technology from any alternative testing and management methodology available to agriculture today -- all of which require the destruction of individual animals and even entire herds. GeneThera's testing and data analysis processes also allow them not only to separate infected from clean animals, but also to gain knowledge vital to development of preventative vaccines.
To view the StockGuru.com Profile for GeneThera Inc., please visit: http://www.stockguru.com/profiles/gtha/
About StockGuru.com
StockGuru.com features free small cap and microcap alerts sent throughout the trading day to members. This service is free to anyone who joins our email list. To join our email alert list, please visit: http://www.stockguru.com/stocks.htm
To feature your publicly traded company in our alerts, or to discuss our services, please contact: John Pentony at (469) 252-3031 or email publisher@stockguru.com. Our services include our Morning Alert, Trade Alerts, Breaking News Alerts and more. Additionally, we profile publicly traded companies, we interview key executives with these companies, and we share news about these companies with our membership.
"Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.
Disclosure: Pentony Enterprises LLC was compensated 500,000 free trading shares from a non-controlling third party for profile coverage. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.